InMed Pharmaceuticals Inc. Quarterly Revenues in USD from Q4 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
Summary
InMed Pharmaceuticals Inc. quarterly/annual Revenues history and growth rate from Q4 2021 to Q3 2024.
  • InMed Pharmaceuticals Inc. Revenues for the quarter ending September 30, 2024 was $1.26M, a 40.2% increase year-over-year.
  • InMed Pharmaceuticals Inc. annual Revenues for 2024 was $4.6M, a 11.2% increase from 2023.
  • InMed Pharmaceuticals Inc. annual Revenues for 2023 was $4.14M, a 280% increase from 2022.
Revenues, Trailing 12 Months (USD)
Revenues, Quarterly (USD)
Revenues, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $1.26M +$363K +40.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q4 2023 $5.49M $1.24M +$770K +164% Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-13
Q3 2023 $4.72M $902K +$581K +181% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $4.14M $2.31M Apr 1, 2023 Jun 30, 2023 10-K 2024-09-30
Q1 2023 $1.03M +$724K +234% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $470K +$205K +77.2% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-13
Q3 2022 $321K Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q1 2022 $310K Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $265K Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.